Previous 10 | Next 10 |
2023-03-13 08:46:21 ET Capstone Green Energy ( NASDAQ: CGEN ) announced that its authorized distributor in Alaska, Arctic Energy, received new orders from two leading oil and gas operators. The first order is for a C600S microturbine to power a major oil and gas ...
Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference PR Newswire HOLON, ISRAEL , March 8, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in...
Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study PR Newswire Study builds on clinical benefit reported in heavily pretreated MSS CRC patients with liver metastases treated with dual combination of COM701 and niv...
Shares of Compugen (NASDAQ: CGEN) rose more than 10% in early trading Tuesday, a day after the clinical-stage cancer immunotherapy company reported its fourth-quarter and full-year results. While the stock is down more than 73% over the past 12 months, it is up more than 17% so far in 202...
Compugen Ltd. (CGEN) Q4 2022 Earnings Conference Call February 23, 2023, 08:30 AM ET Company Participants Yvonne Naughton - Head, IR and Corporate Communications Anat Cohen-Dayag - President and CEO Henry Adewoye - Chief Medical Officer Eran Ophir - SVP, Research a...
Compugen press release ( NASDAQ: CGEN ): Q4 GAAP EPS of -$0.04 beats by $0.10 . Revenue of $7.5M. As of December 31, 2022, Compugen had ~$83.7 million in cash, cash equivalents, restricted cash and short-term bank deposits compared with ~$117.8 million as of December 31, 2...
Compugen Reports Fourth Quarter and Full Year 2022 Results PR Newswire On track to dose the first patients in MSS CRC and PROC triple combination proof of concept studies in Q1 2023 and Q2 2023, respectively, with the combination of potential first-in-class anti-PVRIG, COM701,...
Compugen ( NASDAQ: CGEN ) is scheduled to announce Q4 earnings results on Friday, February 24th, after market close. The consensus EPS Estimate is -$0.14 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 down...
Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3 PR Newswire Phase 3 study with rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq:AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902 is expected to start in 20...
Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023 PR Newswire HOLON, Israel , Feb. 13, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational tar...
News, Short Squeeze, Breakout and More Instantly...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...